로그인
토토사이트
신규사이트
업체홍보/구인
먹튀사이트/제보
지식/노하우
놀이터홍보
판매의뢰
스포츠분석
뉴스
후기내역공유
커뮤니티
포토
포인트
보증업체
카지노
토토
홀덤
구인
구직
총판
제작업체홍보
카지노 먹튀
토토 먹튀
먹튀제보
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
토토 홍보
카지노 홍보
홀덤 홍보
꽁머니홍보
신규가입머니
제작판매
제작의뢰
게임
축구
야구
농구
배구
하키
미식축구
스포츠뉴스
연예뉴스
IT뉴스
카지노 후기
토토 후기
홀덤 후기
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[]
증권사 코스피 전망치 4,500∼7,500 제각각…투자자 혼란(종합)
N
[]
정부 '헌법존중 TF' 구성…李 "내란 협조 공직자 조사, 당연"[종합]
N
[연예뉴스]
무일푼 시골 소년, 37세에 60억 건물주됐다…650억 호텔까지 매입 (백만장자)
N
[연예뉴스]
MC몽, 집에 걸린 '히틀러 그림' 해명.."예술을 모르니 무식하게" [전문]
N
[IT뉴스]
KT, 오늘부터 유심 '택배 배송' …"본인인증·주소 입력하면 끝"
N
커뮤니티
더보기
[유머★이슈]
바란 은퇴보다 더 소름돋는점
[유머★이슈]
오늘 국군의날 예행연습에 최초 공개된 장비들
[유머★이슈]
손흥민이 한국 병역 시스템에 영향 끼친 것.
[유머★이슈]
시댁의 속터지는 스무고개식 대화법
[유머★이슈]
엄마. 나 여자 임신시켜버렸어
목록
글쓰기
[IT뉴스]Biotech Stocks Rally, Woojung Bio Shaken on Deal Speculation[K-Bio Pulse]
온카뱅크관리자
조회:
1
2025-11-11 09:17:30
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="877eKAJ6mN"> <div contents-hash="5cc1a0f88ae81b246a5e1962dd2152bcbc0f984f710a9c3e3af3b30649d2f249" dmcf-pid="6zzd9ciPDa" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on November 4, 2025, at 9:06 AM. </div> </div> <p contents-hash="9beb98e7a12ef8160f8aabf7f493d63c8ffdbb5c74c788e39774e4f29208531e" dmcf-pid="PJJOgGCEDg" dmcf-ptype="general">[Kim Saemi, Edaily Reporter] On November 3, trading volume for ALTEOGEN Inc, the top-ranked company on the KOSDAQ?increased significantly, indicating a possible inflow of capital into the biotech sector. In the KOSPI market, Il Dong Pharmaceutical Co., Ltd rose sharply following analyst commentary that the stock is severely undervalued. Robotics-related stocks, including Curexo Inc., gained on the so-called “Jensen Huang effect.” Meanwhile, WOOJUNG BIO, Inc. saw wild price swings influenced by a media report from earlier in the day.</p> <p contents-hash="d667e599ecb3790e334bd5fe8c5ddf453a20e7317df9a6d2d012e2825a43f19b" dmcf-pid="QiiIaHhDIo" dmcf-ptype="general"><strong> Il Dong: Undervalued Obesity Drug? Heads to BIO-Europe</strong></p> <p contents-hash="761f84734f894d2c11d5a327c26ceb0d126b2c7cd81ddb8000769c02efff27f2" dmcf-pid="xnnCNXlwwL" dmcf-ptype="general">According to MP Doctor (formerly MarketPoint) by KG Zeroin, Il Dong closed at 27,600 won, up 4,100 won (17.45%) from the previous session.</p> <figure class="figure_frm origin_fig" contents-hash="dbe6630d84f321bc7346ebc837974b784297a185e4409dfccc64efe7087364b2" dmcf-pid="y55f0J8Brn" dmcf-ptype="figure"> <p class="link_figure"><img alt="On November 3, Il Dong Pharmaceutical ranked sixth among the top gainers on the KOSPI. (Source: MP Doctor by KG Zeroin)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202511/11/Edaily/20251111090849242zjuk.jpg" data-org-width="596" dmcf-mid="fRqcRhEoDA" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202511/11/Edaily/20251111090849242zjuk.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> On November 3, Il Dong Pharmaceutical ranked sixth among the top gainers on the KOSPI. (Source: MP Doctor by KG Zeroin) </figcaption> </figure> <div contents-hash="f97f9e7925af7c8cec883ab3db96362a3d79d041372980826db35b4273c45801" dmcf-pid="W114pi6bwi" dmcf-ptype="general"> The sharp rise was likely influenced by a recent report from SK Securities, which assessed that Il Dong Pharmaceutical’s obesity treatment candidate has been significantly undervalued due to market misunderstanding. Earlier, on September 29, the company released topline results from the Phase 1 clinical trial of its oral small-molecule GLP-1RA obesity drug, ID110521156. </div> <p contents-hash="6ab7c27c8231fc4745d213f98ee073978ff567d8297fa1600a562b749476994a" dmcf-pid="Ytt8UnPKsJ" dmcf-ptype="general">The data showed weight reductions of 5.5% and 6.9% in the 50 mg and 100 mg groups over four weeks, respectively. The 200 mg group achieved an average weight loss of 9.9%, with a maximum of 13.8%, confirming dose-dependent efficacy.</p> <p contents-hash="7d91a55dca416cb2aebad6ad7558b6c1abe2b16f3ec2bcbc6699f5ec50c132eb" dmcf-pid="GFF6uLQ9sd" dmcf-ptype="general">Lee Sun-kyung, a researcher at SK Securities, commented:</p> <p contents-hash="74e6b4418a429eba562240b4da5cb2098d4303f139f6d17b9f748875abd02715" dmcf-pid="H33P7ox2Ee" dmcf-ptype="general">“ID110521156 has demonstrated the best safety and efficacy profile among its class, but remains severely undervalued due to market misconceptions. Once this is resolved, Il Dong’s market cap could more than double, ranging between 1.5 trillion and 4 trillion won, in line with similar pipeline licensing deals.”</p> <p contents-hash="d3e1eb60349d8fae497f5ee59760770a78556bf5e1d7b658e2e6736effd3d413" dmcf-pid="XXX2FefzOR" dmcf-ptype="general">Lee added that investor caution stems from failed attempts by Pfizer, Terns, and disappointing results from Roche and AstraZeneca.</p> <p contents-hash="d0c326ff824d6031b53cd97ccccdd9801eefa1d6005220be6ec666c53d7eb7ed" dmcf-pid="ZZZV3d4qEM" dmcf-ptype="general">“The primary reason for these failures has been liver toxicity, limiting the ability to raise dosage levels for effective weight loss. Il Dong’s drug, however, has shown improvement across all liver function indicators,” she said.</p> <p contents-hash="1c850391b7f418a4dab1a1336dbb05a96ab7f1f1a144921a09ec1843abedce1e" dmcf-pid="555f0J8BDx" dmcf-ptype="general">She further emphasized the drug’s potential:</p> <p contents-hash="01cd2e7fe36fb8905e544b513a7a560e776d79263d6cf04850f75dfbc4a8d54a" dmcf-pid="1114pi6brQ" dmcf-ptype="general">“Given its effectiveness during the dosing period, ID110521156 may even surpass Eli Lilly’s oral obesity drug Orforglipron in market potential.”</p> <p contents-hash="eaf3f95f96b25196bb3e9f484c54c4171c3fac77c5da75b721e936d2e9d2e7a0" dmcf-pid="ttt8UnPKwP" dmcf-ptype="general">Il Dong will attend BIO-Europe 2025 to hold partnering meetings for ID110521156 and its potassium-competitive acid blocker (P-CAB) peptic ulcer drug ‘Fexuprazan’. The company aims to accelerate commercialization by sharing updated clinical data.</p> <p contents-hash="6c412e0ff44cb79565cba217d6b5fc84c01042d75499deac9bad4533db5177c9" dmcf-pid="FFF6uLQ9D6" dmcf-ptype="general"><strong> Curexo Gains 6% on ‘Jensen Huang Effect’ and Japan Market Entry</strong></p> <p contents-hash="a8707e1768516704c4fa9267042284ff39720a599f6c98d6fe973b108feb9914" dmcf-pid="333P7ox2s8" dmcf-ptype="general">Curexo Inc. closed at 11,140 won, up 590 won (5.59%). The stock rose alongside other robotics companies following remarks by NVIDIA CEO Jensen Huang, as well as on news of the company’s expansion into Japan.</p> <p contents-hash="6732d2d59619efa18de73bc50eabd92cf916d6974288b482a205072cb732f719" dmcf-pid="000QzgMVw4" dmcf-ptype="general">During his visit to Korea for the APEC summit on October 30, Huang said,</p> <p contents-hash="681758e4a6abeb4ebc8b9bb59c19f31f9a06cd73bc88a58fff7cb413dc3ee616" dmcf-pid="pppxqaRfmf" dmcf-ptype="general">“I have very good news for Korea. it will be related to artificial intelligence and robotics,” prompting increased investor interest in robotics shares.</p> <p contents-hash="9f3174536eb800bcf58f690007c1e50bf984f8b5ae66105376eb945d2ae926aa" dmcf-pid="UffNQOAiOV" dmcf-ptype="general">Curexo also announced that its robotic joint surgery system CUVIS-Joint was successfully installed and used for the first time at Tachibana Hospital in Japan.</p> <p contents-hash="3c88da7885606972ab4588bc9143edd680496589662bf0e2baefe2e148cc3553" dmcf-pid="u44jxIcns2" dmcf-ptype="general">A Curexo official commented:</p> <p contents-hash="e58f7d0be9ff6fd4baeb7f7e152a2ee2c9488311e6a5a2bd3876458810e3b419" dmcf-pid="788AMCkLE9" dmcf-ptype="general">“This marks a critical first step in validating CUVIS-Joint’s technology in the Japanese market. It will serve as a key milestone in expanding into orthopedic surgery in Japan.”</p> <p contents-hash="ab57d86fb4e3751f18a027bce3f54bf1dc4d1638bd8e6518cbed35729a83608e" dmcf-pid="z66cRhEoEK" dmcf-ptype="general"><strong> Woojung Bio Spikes on Takeover Talks?…Companies Deny</strong></p> <p contents-hash="cea0b16848414c781f0936a0778b66e4c3410a57caf41043ba760ab65288decd" dmcf-pid="qPPkelDgwb" dmcf-ptype="general">WOOJUNG BIO, Inc. surged 562 won (29.93%) at the open, hitting the daily upper limit, before trimming gains after 9:30 a.m. The volatility followed the release of a takeover talks via PharmEdaily.</p> <figure class="figure_frm origin_fig" contents-hash="33b7b769c9aa6e15502638b09bf7e3ed5cabe836b63641fb4859e289ada89b37" dmcf-pid="BQQEdSwasB" dmcf-ptype="figure"> <p class="link_figure"><img alt="Woojung Bio headquarters building (Source: Woojung Bio)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202511/11/Edaily/20251111090850487cbhn.jpg" data-org-width="432" dmcf-mid="4uH9tRV7wj" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202511/11/Edaily/20251111090850487cbhn.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Woojung Bio headquarters building (Source: Woojung Bio) </figcaption> </figure> <div contents-hash="7c252e1dfd6c5e30b85b43dee9f2cfbbead1261ae1d99d6511ecc5afcdfa25f2" dmcf-pid="bxxDJvrNsq" dmcf-ptype="general"> On October 2, PharmEdaily published a premium article titled: </div> <p contents-hash="a8d923fcf7eae323a8943e23d64cc807bcca06b0f06c5e823f8d6746885c77f5" dmcf-pid="KMMwiTmjOz" dmcf-ptype="general">“[Exclusive] First-Gen Bio Firm Woojung Bio in Quiet M&A Talks with HLB”</p> <p contents-hash="905be2cca41549e67dbd11c18e4b820a69b818e2085d1c693880197ce091edb4" dmcf-pid="9RRrnysAO7" dmcf-ptype="general">The report was made freely available on a major portal on November 1 at 7:31 a.m., reigniting speculation that led to a sharp price surge when the market opened on November 3.</p> <p contents-hash="b8255326457ca594261aff26f46129d2231de57dfde394c6442fe57d3613fbec" dmcf-pid="2eemLWOcwu" dmcf-ptype="general">As speculation intensified, both HLB bioStep Co., Ltd. and Woojung Bio issued denials.</p> <p contents-hash="55d0e4ae95463cf8d4d09d0e3568b8ef748c5ded739540723438c34e77f2974f" dmcf-pid="VccYrpHlwU" dmcf-ptype="general">HLB bioStep stated:</p> <p contents-hash="3acdd7db3a74f1e748b9518758ba68f6c0971f5c4c4811fedfec553feba27bdd" dmcf-pid="fkkGmUXSIp" dmcf-ptype="general">“There are no active plans to acquire Woojung Bio. The HLB Group is focusing all resources on resubmitting its liver cancer NDA and submitting its cholangiocarcinoma application to the FDA early next year.”</p> <p contents-hash="79ed767c2d828fc0eddd49710d26b737ac84a7d70841b6f77e0f51d7e9e41602" dmcf-pid="4EEHsuZvE0" dmcf-ptype="general">Woojung Bio also clarified:</p> <p contents-hash="6b199649fbff1b5c05df5c9568ab28973b218425603958ef0e8438d26fe10f15" dmcf-pid="8DDXO75Tr3" dmcf-ptype="general">“We have never initiated any sale process.”</p> <p contents-hash="d0cc0d3cb969e5b3fa85dcaaacc2a19b701f67a72263a937f6a3dae519ce19c1" dmcf-pid="6wwZIz1ywF" dmcf-ptype="general">Elsewhere, ALTEOGEN Inc. climbed 34,500 won (7.06%) to close at 523,000 won. Some investors viewed the rally as a positive signal that liquidity may be returning to the biotech sector.</p> <p contents-hash="1e7082fd700e2eee203a7802fbf1a0382406402ee2368c8c28907ff1a24da7e4" dmcf-pid="Prr5CqtWwt" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
놀이터홍보
더보기
[홀덤 홍보]
텍사스홀덤 핸드 순위- 홀카드의 가치
[홀덤 홍보]
텍사스홀덤 핸드 순위 - 프리플랍(Pre-Flop) 핸드 랭킹
[토토 홍보]
미니게임개발제작 전문업체 포유소프트를 추천드립니다.
[토토 홍보]
2023년 일본 만화 판매량 순위 공개
[토토 홍보]
무료만화 사이트 보는곳 3가지 추천
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기